Design, Synthesis, and Biological Evaluation of New 2,6,7-Substituted Purine Derivatives as Toll-like Receptor 7 Agonists for Intranasal Vaccine Adjuvants-Reference-Cited by-同舟云学术

Design, Synthesis, and Biological Evaluation of New 2,6,7-Substituted Purine Derivatives as Toll-like Receptor 7 Agonists for Intranasal Vaccine Adjuvants

Published:2024-05-24 Issue:11 Volume:67 Page:9389-9405
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Kim Morgan¹^ORCID,Noh Kyungseob²³,Kim Pyeongkeun¹,Kim Jae Ho⁴,Choi Byeong Wook¹,Singh Ravi¹,Choi Jun-Ho¹^ORCID,Han Soo Bong²⁵^ORCID,Kim Seong Soon⁶^ORCID,Lee Eun-Young⁴,Bae Myung Ae⁶,Shin Daeho²,Kim Meehyein²³^ORCID,Ahn Jin Hee¹⁴^ORCID

Affiliation:

1. Department of Chemistry, Gwangju Institute of Science and Technology, Gwangju 61005, Republic of Korea

2. Infectious Diseases Therapeutic Research Center, Korea Research Institute of Chemical Technology (KRICT), Daejeon 34114, Republic of Korea

3. Graduate School of New Drug Discovery and Development, Chungnam National University, Daejeon 34134, Republic of Korea

4. JD Bioscience, 208 Cheomdan-gwagiro, Buk-gu, Gwangju 61005, Republic of Korea

5. Medicinal Chemistry and Pharmacology, University of Science and Technology, Daejeon 34113, Republic of Korea

6. Bio and Drug Discovery Division, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea

Funder

Korea Health Industry Development Institute

Korea Research Institute of Chemical Technology

National Research Foundation of Korea

Korea Institute of Energy Technology Evaluation and Planning

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.4c00489

Reference41 articles.

1. Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives

2. Interferon-α induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6

3. Structural Evolution and Translational Potential for Agonists and Antagonists of Endosomal Toll-like Receptors

4. Toll-like receptors mediating vascular malfunction: Lessons from receptor subtypes

5. Targeting Toll-like receptors: emerging therapeutics?